Castle Biosciences

Historical price data

Castle Biosciences is a mission-driven company focused on transforming disease management by applying precision genomics to high-stakes clinical decisions. Since its 2008 founding, it has built a commercially successful portfolio of proprietary tests, supported by over 150 peer-reviewed publications and more than 300,000 test reports delivered. Its strategy centers on addressing critical unmet needs in dermatologic, ocular, and gastrointestinal oncology through its multi-analyte GEP platform, driving growth via clinical validation, payer coverage, and market penetration.

Proprietary multi-analyte gene expression profiling (GEP) and algorithmic interpretation platform, utilizing RNA from FFPE tissue, often integrated with clinicopathologic factors and complementary technologies like IHC and NGS.

Castle competes with specialized diagnostic firms like SkylineDx (melanoma) and Avero Diagnostics (uveal melanoma), as well as standard clinicopathologic approaches. Its competitive edge is built on a robust body of clinical evidence, an integrated test portfolio, and proven commercial execution in securing reimbursement.